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Abstract 
Interpreting randomized clinical trials (RCTs) is crucial to making decisions regarding the 
use of analgesic treatments in clinical practice. In this article, we report on an Initiative on 
Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) consensus meeting 
organized by the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, 
Opportunities, and Networks (ACTTION), the purpose of which was to recommend approaches 
that facilitate interpretation of analgesic RCTs. We review issues to consider when drawing 
conclusions from RCTs, as well as common methods for reporting RCT results and the 
limitations of each method. These issues include the type of trial, study design, statistical 
analysis methods, magnitude of the estimated beneficial and harmful effects and associated 
precision, availability of alternative treatments and their benefit-risk profile, clinical importance of 
the change from baseline both within and between groups, presentation of the outcome data, 
and the limitations of the approaches used. 
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1. Introduction 
Incorporating a treatment for chronic pain into clinical practice requires critical evaluation 
labeling, supplemented by publications in the literature. In turn, evaluating the evidence for a 
particular treatment requires understanding the trial designs (e.g., explanatory trials examining 
whether a treatment has an effect under carefully controlled conditions, and pragmatic trials 
examining whether a treatment has an effect in a general clinical population) [100] and methods 
for presenting data regarding treatment efficacy and safety [69]. When trial designs and 
clinical effect and the ability to compare results between different treatments for chronic pain 
and across diverse populations. Under the auspices of the Analgesic, Anesthetic, and Addiction 
Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION; 
http://www.acttion.org/) public-private partnership with the U.S. Food and Drug Administration 
(FDA), the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials 
(IMMPACT; http://www.immpact.org/) convened a meeting in 2011 to review methods of 
analyzing and reporting the results of randomized clinical trials (RCTs) of pain treatments and 
the limitations of each approach. The focus of this meeting was to develop recommendations for 
improving the understanding and interpretation of RCTs of pain treatments by clinicians and 
other stakeholders who have limited methodologic or statistical expertise. Topics were selected 
to be consistent with research that has identified causes of clinical misinterpretations of RCTs, 
such as understandings of trial summary statistics and defining a clinically meaningful difference 
[2, 79, 98, 123]. Additional topics were considered during the drafting of this article [13, 66, 69, 
70]. This article begins by highlighting explanatory and pragmatic approaches to research. 
Frequently-used methods for describing the benefits and risks of treatments for chronic pain are 






































































IMMPACT organized a meeting to discuss and reach consensus on approaches that 
facilitate interpretation of analgesic RCTs. International representatives from academia, 
regulatory and other governmental agencies, industry, and a pain patient advocacy group 
for IMMPACT meetings is to invite all members of the ACTTION Executive and Steering 
Committees. ACTTION strives to include on these committees individuals from across the world 
representing diverse stakeholders and with expertise or involvement in clinical trial methods. 
This list of invitees is supplemented by inviting individuals with particular expertise in the topics 
to be discussed at the specific IMMPACT meeting. Background lectures were presented by co-
authors of this manuscript to facilitate discussion. Topics included: (1) what clinicians want to 
learn from the results of analgesic RCTs (MCR), (2) responder analyses, cumulative distribution 
-analyses, 
numbers needed to treat (NNT), and Cochrane systematic reviews and other synthesized 
evidence regarding healthcare interventions (CE), and (4) interpreting responder analyses and 
NNTs (available on the IMMPACT website, 
http://www.immpact.org/meetings/Immpact14/participants14.html). During the meeting, the 
content to include in the manuscript and the advantages and limitations of various methods 
used to present RCT results were considered. Multiple revisions to preliminary drafts of this 
article were made until consensus was achieved among all authors. 
 
3. Explanatory vs. pragmatic trials 
When interpreting pain treatment trial results, it is important to consider not only the 
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determine whether the research is designed to answer an explanatory question (i.e., is the 
treatment efficacious within a carefully controlled study?) or pragmatic question (i.e., is the 
treatment effective under real world conditions?); see Table 1 for terms and definitions [42, 100, 
111]
ect and adverse event 
-blind, placebo-
controlled, RCT [24, 53, 92]. RCTs of pain treatments are internally valid to the extent that they 
are rigorously controlled to minimize effects on outcomes that are not caused by the study 
treatment. Participants should be selected to maximize the probability of observing a treatment 
effect if one exists (e.g., including enough patients to have adequate power to detect a clinically 
meaningful difference between the treatment and control groups, minimizing concomitant pain 
treatments, comorbid pain conditions, rescue medication, and variability in the pain experience). 
Identifying a treatment effect if one exists can be accomplished by having strict eligibility criteria, 
keeping patients and study staff blinded to the protocol (e.g., randomization criteria, treatment 
group assignments, study start point, analysis time point for the primary efficacy endpoint) when 
possible, limiting concurrent treatments, performing power calculations with the best available 
estimates of required parameters (e.g., standard deviation of the outcome variable), measuring 
outcomes that are meaningful and interpretable in the population studied, and randomizing 
patients to ensure unbiased assignment to treatment. Explanatory trials are conducted to 
generalize to the wider population of individuals with a particular chronic pain condition who are 
treated in clinical practice [39, 41]. 
Once a treatment has been shown to be efficacious and safe for a specific chronic pain 
condition within the setting of carefully controlled clinical trials, it is also important to determine 
whether the treatment is effective in the broader population of individuals with that condition in 
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compared to other standard treatments may help establish the clinical application of the 
treatment. Pragmatic trials are designed to evaluate the treatment in a more heterogeneous 
sample, as may be the case within a clinical patient population in which effect modifiers (e.g., 
comorbid pain conditions, various concurrent treatments, variability in the pain experience) are 
more likely to play a role [39, 41]. Such trials may yield a more generalizable estimate of the 
treatment effect and therefore may be more externally valid, but can be less informative with 
respect to understanding the potential impact of treatment due to the variability permitted in trial 
conduct. Identifying factors that might alter the treatment effect in pragmatic trials may enhance 
the ability to understand the clinical utility of a treatment; however, such investigations are often 
limited by insufficient sample sizes. 
Explanatory and pragmatic trials each contribute distinct information to the evidence 
available regarding pain treatments. Explanatory trials address whether treatments have health 
benefits or risks, whereas pragmatic trials explore the bounds within which beneficial analgesic 
outcomes can be observed in study populations. Establishing whether treatments are 
efficacious and the broader circumstances under which they work are each important for clinical 
decision-making [100]. The tradeoffs between precision and external validity in explanatory 
versus pragmatic trials must be considered when interpreting the results of these two 
complementary classes of trials. In some cases, study designs that blend these two approaches 
may accelerate the speed with which pain treatments can be translated into clinical practice [97, 
120].  
 
4. Determining treatment benefit 
4.1. Hypothesis testing, confidence intervals, and P-values 
To adequately evaluate the evidence of efficacy provided by a statistically significant 
treatment group difference in the primary analysis, several issues must be addressed. Foremost 
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specified (i.e., decided upon before analyzing the trial data), and whether the problem of 
multiplicity (i.e., performing multiple analyses), if applicable, was addressed in a satisfactory 
manner to prevent inflation of the probability of a type I error (see Table 1 for definitions of 
terms). Additional important considerations include whether there were any flaws or potential for 
bias in study planning, design, execution, and analysis of the trial data and whether the results 
for important secondary outcomes were consistent with the primary analysis [60, 94]. It is also 
important to evaluate the extent to which the results of the RCT suggest that the treatment 
provides a clinically important benefit, as discussed below. 
When the primary analysis of an RCT indicates that the difference between treatment 
groups is not statistically significant, one possibility is that there was a type II error, that is, the 
treatment is truly efficacious, but the RCT failed to identify the treatment benefit. This can 
happen for a variety of reasons, including a sample size too small to detect a treatment effect of 
minimal clinical importance, or problematic study design or execution that resulted in poor 
quality data and inadequate assay sensitivity [25]. However, assuming that there was sound 
study design and execution [93], it is important to decide whether the results should be 
interpreted as the absence of a clinically meaningful treatment effect or whether they should be 
considered inconclusive. A useful aid to making this decision is to assess the confidence 
interval (CI) for the treatment effect (see Figure 1). Specifically, if the CI for the treatment effect 
does not contain values that would be considered clinically meaningful treatment effects, then 
the trial results can be interpreted as evidence for the absence of a clinically meaningful 
treatment effect. Example 1 in Figure 1 is a trial in which the primary analysis did not yield a 
statistically significant result and the estimated magnitude of the treatment effect (i.e., the range 
of values that fall within the upper and lower CIs) was not clinically meaningful. In contrast, 
Example 5 shows a trial in which the treatment effect was found to be non-zero according to the 
hypothesis test, but the estimated magnitude of the treatment effect was not clinically 
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meaningful, however, the results of a trial in which the treatment effect was not statistically 
significant would be considered inconclusive (see Examples 2 and 3 in Figure 1). In Example 4, 
there is evidence for the absence of a beneficial treatment effect, but the evidence regarding 
superiority of the control is inconclusive. Of course, such results may provide the basis for 
furthe [48]. Although for many years 
biostatisticians have recommended this approach to interpreting results of clinical trials in which 
the treatment effect was not statistically significant, a recent systematic review found that proper 
interpretation of CIs occurs infrequently in general medical journals [44]. 
The importance of examining CIs when interpreting pain RCTs can be seen in trials in 
recommended for treatment of 
painful diabetic peripheral neuropathy (pDPN) by international treatment guidelines and is 
approved for treatment of neuropathic pain in both the US and Europe [7]. However, certain 
trials of individuals with pDPN have demonstrated statistically non-significant separation 
between pregabalin and placebo on pain outcomes, which are interpreted as indicating that the 
trial is negative. For example, a study conducted by Raskin and colleagues found a treatment 
effect (pregabalin  placebo) of -0.32 (95% CI, -0.74 to 0.09) on the primary outcome variable 
(i.e., change in pain intensity) [96]. Based on this result, the authors concluded that the study 
deration 
of the CI in this study suggests that the trial was inconclusive, rather than negative, given that 
the CI included results consistent with what could be considered a clinically meaningful 
decrease in pain intensity for pDPN (i.e., > 0.50) associated with pregabalin [23]. 
Systematic reviews of RCTs in the general medical literature [12] and for pharmacologic 
and invasive treatments for pain [45] have also shown that erroneous or misleading 
interpretations of treatment effects that are not statistically significant are quite common. For 
example, authors often suggest that two interventions are equivalent when an RCT fails to show 
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been designed to test superiority rather than equivalence, as is the case for most RCTs of pain 
treatments. Conclusions of equivalence require that the treatment effect fall within prespecified 
margins of equivalence that are clinically justified [78, 95]. Additionally, common examples of 
include emphasizing statistically significant results of secondary analyses, solely focusing on 
improvements from baseline in the active treatment group rather than differences between the 
active group and the placebo or comparison group, or highlighting the upper bound of the CI for 
the treatment group difference to suggest a meaningful positive effect. It is important for the 
reader to attend to the primary question that the trial was designed to answer and not be misled 
by secondary outcomes or analyses that only report effects within a treatment group. 
The use of p-values in the context of scientific reporting has come under intense scrutiny 
in recent years due to their misuse and misinterpretation. For example, a common 
misinterpretation of a p-value is that it is the probability that the null hypothesis (of, say, no 
effect of treatment) is true. In fact, the p-value is the probability that a treatment effect larger 
than that observed in the trial would occur under an assumed statistical model if the null 
effective if it is statistically significant (e.g., p < 0.05) is flawed, as is the interpretation that a 
treatment is ineffective if the result is not statistically significant (e.g., p > 0.05). Indeed, the sole 
use of strict dichotomies with respect to p-values to judge whether or not a treatment is effective 
is highly problematic. For example, the level of evidence with respect to the existence of a 
treatment effect is certainly not qualitatively different when p = 0.0499 and when p = 0.0501. 
Another major problem with the misuse of p-values in clinical trials is the failure to account for 
multiplicity when several hypotheses are being tested, particularly with respect to secondary 
analyses (e.g., secondary outcome variables, multiple group comparisons, and subgroup 
analyses). 
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given null hypothesis, they do not convey any information regarding the clinical meaningfulness 
of the treatment effect. With a large enough sample size or low variability in outcomes, an 
observed treatment effect that is clinically insignificant can be associated with a statistically 
significant result [121]. Conversely, as discussed above, a trial with a small sample size or high 
variability in outcomes can yield a large estimated treatment effect that is not statistically 
significant. Understanding the potential clinical importance of a treatment effect requires more 
information, such as the estimated magnitude of the effect and the associated CI around that 
effect. 
Useful discussions of the issues surrounding p-values and their interpretation can be 
found in recently published series of articles [121, 122] and the references therein. In the spirit 
of improved reporting, the CONSORT 2010 checklist recommends reporting the effect size 
estimate and some measure of the precision of that effect estimate [99]. In addition, many 
journals are moving toward reporting the effect size, the associated confidence interval, and the 
exact P-value rather than P < 0.05 [11, 50, 72], with at least one journal requiring that only effect 
size estimates and 95% CIs (with no P-values) be reported when researchers do not have a 
prespecified method to adjust for multiple analyses [50].  
 
4.2. What is a clinically important benefit? 
Statistically significant evidence of a 
indicate that the magnitude of the treatment effect is clinically important. For example, if the 
 
even though they are clinically irrelevant. Evaluations of clinical importance must distinguish 
between determining whether the mean improvements are important to patients or whether the 
group differences between treatments in an RCT are clinically important. A third type of 
evaluation involves determining whether the benefits of a treatment are meaningful to society 
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consideration but one that is beyond the scope of this article. 
 
4.2.1. Clinical importance of improvements in individual patients 
Determining the magnitude of reduction in pain that is meaningful to patients with acute 
or chronic pain is important to the field of pain. Results of this research indicate that reduction in 
pain intensity of 10-
rovement in pain intensity, whereas 
intensity for individuals with acute and chronic pain [15, 27]. However, the importance of such 
decreases could differ dependin
decrease in pain from 8 to 6 on a 0-10 NRS, which can be considered a reduction from severe 
to moderate pain, might be more important to a patient than a reduction from 3 to 1, both of 
which are mild levels of pain. Alternatively, as Hanley et al. [49] have shown, individuals with 
higher pain intensity at baseline require a greater reduction in pain intensity for it to be 
considered a meaningful decrease. It may also be possible that two individuals experience a 
reduction in their pain intensity by the same approximate percentage, but for individual A, the 
pain decreases from a 5 to a 3 on the 0-10 NRS, whereas for individual B, the pain decreases 
from an 8 to a 5. Although the treatment leads both to experience a 38-40% reduction in pain 
intensity, individual A may judge the current level of pain to be acceptable, whereas individual B 
may experience the reduced level of pain as unsatisfactory [109]. Nevertheless, percentage 
reduction in pain is generally considered a useful approach to determining whether a patient has 
had a meaningful improvement than an absolute change on an NRS [27, 36, 89, 90].  
Decreases in pain intensity, however, do not necessarily correspond to the magnitudes 
of overall improvement preferred by patients [38, 46]. For example, a clinically important 
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related quality of life unimproved or even worsened as a result; conversely, treatment might be 
associated with a modest decrease in pain but substantial improvements in sleep, mood, and 
function that taken together would be considered a major benefit by the patient.  
 
4.2.2. Clinical importance of group differences in a clinical trial 
The determination of the level of improvement patients consider clinically important is 
very often confused with evaluation of the group differences between an active and a control 
treatment. Thresholds for meaningful within-patient change (e.g., a reduction of 2 points on a 0-
10 pain intensity NRS) should not be confused with the evaluation of what constitutes a 
meaningful difference between treatment groups. The determination of the clinical importance of 
group differences in RCTs depends on a constellation of factors, including: (1) the magnitude of 
the group difference observed in the trial and its associated CI; (2) the broader context of the 
disease being treated, including whether other treatments are available; (3) adverse events 
associated with the treatment, and (4) an overall evaluation of the benefit-risk profile, ideally as 
assessed by patients, clinicians, researchers, statisticians, and other stakeholders [20, 23, 47, 
71, 98]. For example, a reduction in pain intensity of at least 2 points on a 0-10 NRS could be 
used to define a clinically meaningful improvement for an individual patient, but the difference in 
mean change from baseline between an active treatment and placebo does not necessarily 
atment to be considered clinically important. 
The interpretation of meaningful change depends on whether it is being considered at the group 
level (where smaller between group differences in changes from baseline may be interpreted as 
important) or at the individual level, where thresholds for meaningful change are typically based 
on input from patients regarding what they consider important [10]. 
A number of factors can be considered when evaluating the clinical importance of group 
differences in an RCT (see Table 2). The first consideration is that there must be a statistically 
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addition, the group difference (e.g., as assessed by the standardized effect size) with respect to 
the primary outcome variable can be compared with the effects associated with other treatments 
that are considered to have clinically important benefits. If the treatment effect in an RCT of a 
new treatment is comparable to, or greater than, the effects seen with established therapies, 
then the improvement is likely to be clinically important, although studies confirming this finding 
would be necessary. If the treatment effect found with the new treatment is substantially smaller 
than what has been found for existing therapies, then it becomes essential to evaluate whether 
there are any other characteristics of the new treatment that might compensate for the modest 
treatment effect on the primary outcome variable and make the overall benefit clinically 
important. Other characteristics to consider include safety and tolerability, results for secondary 
efficacy outcomes including physical and emotional functioning, limitations of existing 
treatments, and the other factors listed in Table 2. Importantly, cross-study comparisons of 
different treatments may not reflect what would occur if the different treatments were compared 
within the same study. 
 
4.3. Placebo response and placebo effect 
The placebo effect, or expectations of a treatment benefit, can play a role in the 
observed treatment benefit [33]. The placebo effect has neurobiological and physiological 
mechanisms that are activated by situational effects, interpersonal interactions, verbal 
suggestion, conditioning processes that include prior experiences with treatments, and other 
nonspecific effects [17, 33]. This differs from the placebo group response, which captures all 
changes that occur for patients when an inactive substance is administered, including 
regression to the mean, disease natural history, and the mechanisms associated with the 
placebo effect [33]. In RCTs for pain clinical trials, placebo group responses appear to have 
increased over time, perhaps due to increasing placebo effects, which makes it more difficult to 
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to identify and understand the expectations of study participants by conducting a 3-arm trial of 
which one involves no intervention or by assessing participant expectations [17, 119]. 
 
4.4. Analysis of means 
In pain clinical trials, the mean change in the primary outcome measure (i.e., the 
prespecified measure on which a difference between the treatment and the control group is 
expected) from the baseline pretreatment period to a designated time point after initiation of 
treatment for each treatment arm is typically reported (i.e., within-group change). Within-group 
changes indicate the average change (or no change) that is observed during the course of the 
study for participants in each treatment arm. However, formal analyses of within-group change 
do not address the true objective of the RCT  evaluating whether the difference between 
treatment arms over the course of the study is statistically and clinically significant. In some 
instances, researchers will employ analysis of means testing such as a t-test or analysis of 
variance (ANOVA) to compare the mean within-group changes between treatment arms. An 
analysis strategy that makes more efficient use of the baseline information is analysis of 
covariance, for which the statistical model includes treatment group and the baseline value of 
the outcome variable as independent variables. This strategy yields a more precise estimate of 
the treatment effects than the simple group comparison of mean within-group changes from 
baseline since the latter strategy incorporates the baseline value in a very limited way (i.e., only 
in the definition of the outcome variable) [102, 104]. Studies that only report the statistical 
significance of within-group changes for each treatment arm without statistical comparisons 
between the groups fail to demonstrate that a treatment provides any benefit beyond a placebo 
(or other comparator), as changes from baseline can be due to many factors other than the 
treatment effect (e.g., regression to the mean, symptom fluctuations, contextual influences). It is 
necessary to show that the changes from baseline are greater for one treatment group than the 
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When incorporating a treatment into a clinical setting, it is important to recognize that 
comparisons of group means indicate what is happening on average across all participants, and 
as is the case for all analyses used in trial designs other than multi-period cross-over studies, 
they are not informative about the responses of an individual patient [27, 68, 101]. For example, 
although an RCT may show that patients who receive a specific treatment report greater 
analgesic benefit, on average, than those who receive placebo, patients in the treatment and 
placebo arms may experience improvement, no change, or even increases in pain. Of course, 
while this point has often been made about group means, it applies to any group-level estimand 
 
 
4.5. Responder analyses 
An alternative way to analyze RCT data is to compare the treatment groups with respect 
to the percentage of patients whose improvements meet a pre-defined threshold. Common 
examples are categories of severity such as mild, moderate, or severe pain, or categories of 
 
There is a lack of consensus regarding the pros and cons of responder analyses, and the 
related metric of number needed to treat (NNT). Presenting responder analyses can simplify the 
interpretation of trial results, allowing for a straightforward comparison of the proportion of 
patients in each treatment arm who experienced a pre-defined level of improvement on the 
outcome of interest [34]. However, responder analyses require an understanding of what is 
clinically meaningful to different stakeholders in or
other words, how much within-patient improvement in pain intensity is necessary for patients, 
clinicians, or other stakeholders to identify the pain reductions as clinically meaningful? As 
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considered substantial improvement [27] [49]. 
characteristic of the participant, implying that the participant will respond to the treatment 
regardless of context. In fact, multiple randomized exposures to both the treatment and a control 
are necessary to determine whether or not a patient responds to the treatment [21, 105]. An 
important limitation of using proportions in responder analyses is the loss in statistical power 
-
zation sacrifices information; for 
example, consider that a patient who has a 29% reduction in pain intensity would not be 
that their pain reductions are nearly identical, and the patient with the 29% reduction may 
consider that reduction meaningful [4, 103, 108].  
 
4.6. Cumulative distribution functions (CDFs) 
A challenge previously discussed regarding responder analyses is that investigators 
must specify the decrease in pain intensity that must occur for study participants to be 
have reported one or more distinct levels of reduction in pain intensity does not provide 
complete information about the trial. When contemplating use of a treatment in a clinical setting, 
clinicians may want to know the percentages of participants in each group who experienced 
different levels of reduction in pain intensity (e.g., 20% or 75% reduction). Farrar and colleagues 
proposed an alternative method of reporting RCT results, cumulative distribution functions 
(CDFs), which graphically depict a continuous plot of the percentages of participants in each 
treatment arm across the entire range of possible responses (see Figure 2 for an example) [35]. 
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the full range of improvement. In this way, readers can apply their own definitions of a 
meaningful improvement when interpreting the results. Multi-tiered information, in conjunction 
with analysis of means, can be valuable in establishing whether the treatment benefit is clinically 
meaningful to patients [23, 114]. Presenting CDFs allows the reader to identify the percentages 
groups. In addition, the difference between the CDF cur
absolute risk reduction (ARR), which can then be used to calculate the NNT (see below).  
CDFs are a useful descriptive tool that can visually depict the data from an RCT. As with 
any RCT analysis, it is important that the problem of missing data is addressed before 
computing the CDF. Often, researchers presume that anyone who drops out of an RCT is a 
-
dropout is unrelated to treatment. Methods to accommodating missing data are briefly 
addressed in section 7 below. 
 
4.7. Number needed to treat (NNT), number needed to harm (NNH), and relative risk (RR) 
The NNT is a value that summarizes a treatment group comparison with respect to the 
[74, 82]. The NNT 
is calculated as 1/ARR, or the absolute risk reduction. The ARR reflects the difference between 
treatment groups in the percentages of participants experiencing an event (e.g., difference in 
 The NNT indicates 
the expected number of people who would need to take the treatment for there to be 1 
arm [5, 66]. It can be calculated from the difference between the two CDF curves at a particular 
 
As is the case for responder analyses, the NNT is designed to simplify RCT 
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diagnoses. For example, consider a hypothetical 16-week RCT comparing an analgesic 
pa
40% of the participants in the analgesic treatment arm and 20% in the placebo arm are 
 0.20 = 0.20, and the NNT would be 1 / (0.40  0.20) = 5. 
The interpretation would be that if 5 individuals took the treatment for 16 weeks, 2 would be 
placebo for 16 weeks, 1 would be expected to meet 
treatment versus those administered placebo [66]. The number needed to harm (NNH) is 
calculated in the same way using the incidence of adverse events (AEs) or other safety 
outcomes in the treatment and comparator arms over a given time period [5, 28, 82]. The NNH 
can be misleading, however, particularly if it aggregates AEs of varying severity and 
seriousness (e.g., if mild dry mouth and death are equally weighted when counting AEs). Thus, 
NNH calculations are much less frequently found in RCT reporting than NNT calculations. 
between two treatment arms in a study, providing information about the likelihood of achieving a 
[1, 52]. The RR is calculated by dividing the percentage of patients who are 
acebo 
arm [1, 52]. Using the same example of an RCT where 40% of the analgesic treatment arm 
he analgesic 
connotes harm, the interpretation of relative risks could be facilitated if the risks of nonresponse 
were presented (i.e., (100%-40%)/(100%-20%) = 0.75), indicating that the RR of nonresponse is 
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between the two treatment groups [92]. The ARR may be more informative to clinicians and 
patients than the RR, however, in that it describes the difference in the incidence of the event of 
 0.20 = 
0.20 or 20% difference in event incidence), rather than describing the relative probability of 
[1]. An RR of 2.0 could reflect very different ARRs, such as 20% 
(40%  20%) or 5% (10%  5%). Relative risks presented without the absolute risk are a 
common cause of confusion, in which the risk to an individual can appear exaggerated. 
The limitations of the NNT mirror those of responder analyses, given that the NNT is 
based on categorizing study patients as having met a pre-defined threshold of improvement 
from baseline. Additionally, the NNT is frequently misinterpreted as indicating the number of 
[66], rather than the 
number of patients who would need to take the treatment for there to be 1 additional 
this distinction is important. Using the example above, the NNT of 5 does not mean that we 
would expect 1 person 
than there would be among 5 patients taking placebo. It is also important to recognize that an 
NNT that is calculated using a specific threshold can be incorrectly compared to an NNT 
calculated with a different threshold (e.g., an NNT calculated using a 30% reduction in pain 
n NNT calculated using a 
50% reduction) [35, 108].  
There is a lack of consensus among the authors regarding whether NNTs contribute to 
the interpretation of RCTs and the extent to which they are incorrectly interpreted. As an 
mparing paracetamol to a placebo for treating tension headache. 
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were treated with paracetamol. The difference is 10% and the NNT is 10. However, if 
paracetamol works for 100% of participants in 60% of the times they are treated, it will give the 
same NNT as if it works for 60% of the participants 100% of the time. A high NNT should not be 
taken to imply that a drug works really well for a specific, narrow subset of people. It could 
-1) [106]. For 
additional reading on the limitations of NNTs, see also [66, 79].  
 
4.8. Time to effect and duration of effect 
Beyond identifying the effect of a treatment, data on the temporal course of that effect 
can provide information regarding the time to onset of a beneficial effect and how long the 
beneficial effect lasts. These details provide clinicians and patients with a more comprehensive 
understa [22]
course data may be valuable for interpreting treatment effect, there is no standardized method 
to assess time to effect or duration of effect. One possibility, for example, is to graphically 
allowing the reader to interpret the time course. It may also be informative to present data 
indicating when the mean pain intensity in the treatment arm first demonstrates a statistically 
significant or clinically meaningful separation from the placebo arm, although this may conflate 
time to onset with sample size. Additionally, data regarding time to a clinically relevant event 
(e.g., minimal pain, discontinuation of treatment) in each treatment arm can be used to assess 
the time to onset of a beneficial effect. In acute pain RCTs, for example, researchers may use 
the double stopwatch method to capture the onset of first pain relief, as well as the onset of 
meaningful pain relief [73]
each assessment period separated by treatment arm. Reports of RCTs may use different 
, making it difficult to compare the 
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chronic pain RCTs. A further limitation is that few studies are conducted to examine the long-
 effect. Frequently the only available data on the duration of a 
see [16, 64, 83] showing that the double-blind period of opioid analgesic trials is frequently 6 
weeks or less); such data cannot speak to the effect of the treatment when used over an 
extended period of time as might be expected in many chronic pain conditions.  
One approach that may provide information about the duration of analgesic effect is an 
adaptation of the randomized withdrawal design. In randomized withdrawal studies, all patients 
initially receive active treatment and are then randomized to stay on active treatment or receive 
placebo [84]. At the end of the treatment period, individuals in both the treatment and placebo 
arms who meet some pre-defined threshold (e.g., >30% reduction in pain intensity) could be 
followed to determine the duration of the treatment effect in a double-blind long-term efficacy 
study [75].  
 
5. Treatment risks 
A comp
results, but safety (i.e., AEs identified through patient symptoms or clinically assessed signs) as 
well. AEs provide important information regarding the tolerability and safety of a treatment, and 
example, adverse treatment effects have been shown to be associated with increased reports of 
pain interference beyond the effect of pain intensity itself [77], suggesting that it is not a 
published guidance for comprehensive and transparent reporting of AEs occurring in an RCT 
[58] (see also [43]). It is important to recognize that AEs are not all equivalent, in that the 
seriousness and severity of the AEs affect when a clinician might opt to introduce the treatment. 
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treatment options have been exhausted and the patient is debilitated by their symptoms. For 
AEs that are mild or moderate in severity, the treatment might be discussed with a patient at an 
nefits and side effects. 
In addition to documenting the types and numbers of AEs occurring in an RCT, it is 
essential for reports of RCTs to describe the methodology for acquiring data regarding AEs. For 
example, with passive capture, AEs may be collected solely when study participants self-
and ask the subject if (s)he has experienced each AE. Research has shown that passive 
capture can result in underestimation of the harms experienced by study participants [6, 9, 67], 
although active capture has the potential to overestimate the number of harms observed. The 
methods used to capture AEs should be prespecified and described in articles reporting RCTs 
so the adequacy of the methods can be evaluated. Other critical details regarding potential 
treatment harms that should be reported are: (1) the number and nature of the specific AEs that 
were identified and reported throughout the trial, (2) the severity of the AEs (i.e., mild, moderate, 
severe), (3) definitions of each severity grade, (4) occurrence of serious AEs (SAEs; e.g., 
hospitalization or death) [115], (5) whether or not the AEs were considered to be plausibly 
associated with the treatment (i.e., adverse reactions), and (6) whether standardized coding 
methods (e.g., MedDRA; http://www.meddra.org) were used to class
across trials. It is also necessary to consider the length of the RCT, given that the risk of harm 
may occur after long-term use, rather than in 12-16 week trials.  
Systematic reviews of pain trials have shown that investigators do not always report all 
study AEs [54, 107, 124]. Instead, subsets 
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truncated AE reporting is likely due in part to a desire to briefly summarize study AEs, as well as 
to meet limitations imposed by journal publishers. One drawback of reporting subsets of AEs is 
that rare AEs with possible serious clinical implications may not be adequately disclosed. Solely 
reporting the AEs that demonstrate a statistically significant difference between treatment arms 
can be misleading because the RCT may not have been sufficiently large to detect differences 
in the incidence of certain AEs between treatment arms [3, 56, 57, 63, 112]. Alternately, 
apparently statistically significant differences in AEs between treatment arms may be false 
positives that arise from multiple statistical tests without any adjustments for multiplicity [40]. 
Adequate AE reporting, therefore, involves reporting the denominator for all AE data and 
reporting both the number of events and the number of study participants who experience each 
AE that causes study withdrawal, as well as the moderate, severe, and serious AEs that 
occurred during the study [58, 107]. Additional AE detail could then be made available in online 
journal supplements [107]. 
 
6. Summarizing and integrating treatment benefits and risks 
benefits alongside its risks. Benefit-risk evaluations can be used to guide individual treatment 
decisions by patients and their clinicians, and can also be made at the societal level as a basis 
for regulatory approvals, reimbursement decisions, and medical policies. However, it can be 
practically difficult to weigh the benefits against the risks. Developing a standardized method to 
integrate treatment benefits and risks in order to provide an easily interpretable metric that 
-risk profile is a complicated endeavor and currently no single, 
well-accepted method exists. Furthermore, determining whether treatment benefits outweigh the 
risks may require information about the medical history and preferences of the individual patient 
who will receive the treatment. Despite these challenges, there are several approaches to 
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important to highlight. 
systematic review, meta-analysis, or integrated benefit-risk methods. Conducting a systematic 
review to identify all research published on a specific analgesic treatment, combining the 
efficacy data and the AE data across all trials, and analyzing those data is an effective way of 
consolidating the available evidence. There are limitations to meta-analyses, however. One 
concern is that the quality of the meta-analysis depends upon the quality of the research that 
goes into it. Poorly designed and executed studies are likely to be biased in a variety of ways 
(e.g., selection bias, performance bias), which affects the validity of their results, and this risk of 
bias should be accounted for in the meta-analysis [52]. Meta-analyses also require a method to 
aggregate trial outcomes that may not have been assessed in the same manner (e.g., 
continuous outcomes, time to effect outcomes). Furthermore, meta-analyses may be no better 
than post-marketing safety surveillance at identifying rare events that have not been previously 
identified [81]. Meta-analyses also tend to include only published data. Given a well-known 
reporting bias whereby study results that fail to show a treatment effect are less likely to be 
published, meta-analyses can be biased toward demonstrating a treatment effect that is larger 
than the true treatment effect [52, 80]. Despite these limitations, meta-analyses can provide 
relati
inform clinical practice. Cochrane has developed comprehensive guidance regarding the 
conduct of systematic reviews and meta-analyses for treatment interventions [52], including the 
adoption of Grades of Recommendation, Assessment, Development, and Evaluation (GRADE). 
GRADE is an approach designed to evaluate the risk of bias in individual studies, and to provide 
a rating of confidence in the overall estimate of any effect and the likelihood that the estimate 
could be changed by additional data [8]. 
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benefit-risk frameworks may be qualitative, quantitative, or include both qualitative and 
quantitative components [86]. Qualitative frameworks include visual displays (i.e., tables, 
figures) that list key benefit and risk attributes [86]. One example of a qualitative benefit-risk 
-Risk Integrated Assessment [116]. This structured framework is 
in a tabular format that allows reviewers to synthesize the evidence of the therapeutic context 
(i.e., analysis of the condition and current treatment options) and evidence supporting the 
benefit and risk and risk management strategies of the product that weighed in their decision-
making. The European Medicines Agency (EMA) has issued a guidance document that 
addresses benefit-risk assessment that does not recommend a specific quantitative 
methodology, but is open to considering these approaches on a case-by-case basis [29]. 
-risk assessment that 
includes both qualitative and quantitative components is the Benefit Risk Action Team (BRAT) 
framework [18]. The important features of this approach include identifying the research context 
(e.g., condition being treated, treatment comparator) and the essential benefits and risks across 
studies, and then presenting the data regarding those benefits and risks in a way that can be 
easily understood (e.g., plots of differences in benefits and risks between treatment groups; see 
[18] for an example). This may assist clinicians in interpreting the overall benefit-risk profile, 
which can be integrated with their clinical expertise when treating patients. A more recent review 
identified 49 different methodologies to conduct quantitative and systematic benefit-risk 
assessment of medications [85]. These methods range from descriptive to more quantitative. 
The problem, objectives, alternatives, consequences, trade-offs, uncertainty, risk and linked 
decisions framework (PrOACT-URL) provides another method to descriptively report the risks 
associated with a treatment [85] (see http://protectbenefitrisk.eu/PrOACT-URL.html for 
examples). Other more quantitative methods include multi-criteria decision analysis (MCDA) 
that compares treatment options based on weighted benefit and risk criteria [76, 88], stochastic 
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reflects the treatment risks divided by the benefits [85], stated-choice surveys of willingness to 
accept risks [61] or discrete choice experiments [85], and health outcomes modeling using the 
quality-adjusted life-year (QALY) [19].  
Typical benefit-risk analyses involve separate intervention comparisons for each 
efficacy, safety, and quality-of-life outcome. Outcome-specific effects are tabulated and 
combined (systematically or unsystematically) in benefit-risk analyses so that such analyses can 
describe the totality of effects on patients. However, such approaches do not incorporate 
associations between outcomes of interest, fail to summarize the cumulative nature of different 
outcomes on individual patients, and suffer from competing risk challenges when interpreting 
individual outcomes. In addition, because efficacy and safety analyses are conducted on 
different subsets of participants, the population to which these benefit-risk analyses apply is 
unclear. New benefit-risk methodologies continue to be developed such as the desirability of 
outcome ranking (DOOR) and partial credit which attempt to address the limitations of prior 
methods by ranking various study outcomes using predetermined criteria [30-32]. 
 
7. Select Areas of Advancement for Clinical Trials 
In 2010, the National Research Council (NRC) produced a report on The Prevention and 
Treatment of Missing Data in Clinical Trials [87], and in 2019 an addendum to the ICH E9 
guidance on Statistical Principles for Clinical Trials [55] was released, leading to a major shift in 
how clinical trialists think about trial design and analysis. The NRC report drew attention to the 
significant limitations of existing simplistic methods for dealing with missing data, such as 
carrying forward the last (or baseline) observation. They also emphasized the use of more 
principled methods to deal with the problem such as direct likelihood methods (e.g., mixed 
model repeated measures, or MMRM), multiple imputation, or generalized estimating equations. 
Because any method to deal with missing data is based on untestable assumptions, the NRC 
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analyses (i.e., analyses that make different assumptions concerning the distribution of the 
missing values given the observed data) to determine the degree of the dependence on the 
inference concerning the treatment effect on these assumptions. 
The ICH E9 draft addendum discusses the importance of precise formulation of the 
estimand(s) of interest based on the study objectives [55]. The estimand consists of (1) the 
patient population of interest, (2) the outcome variable, (3) how post-randomization events 
(intercurrent events) will be handled, and (4) the population-level summary for the outcome 
variable. In particular, much thought needs to be given to how to deal with intercurrent events in 
formulating the estimand. The most common intercurrent events include dropout, 
discontinuation of the study intervention, use of prohibited medications and other protocol 
violations, and use of rescue medication [14]. The choice of an estimand depends on the 
characteristics of the treatment (e.g., disease modifying vs. symptom control), setting of 
treatment use (e.g., the ability to monitor outcome over time), and the choice of the control 
group [55].  The estimand has a major influence on the study design, the data to be collected, 
and how the data should be analyzed [14]. 
The vast majority of clinical trials in pain have used standard parallel group or cross-over 
designs. Some advances in trial design that are beginning to be used in the pain field include 
cross-over trials with multiple periods, enrichment, methods to reduce the amount of 
improvement in placebo groups, adaptive designs, and master protocols. A summary of these 
trial designs is provided in Table 3. 
8. Research Agenda 
Improving the interpretation of trial data in clinical or public health decision-making 
research would make an important contribution in a number of related areas. First, models of 
shared decision making that include data from meta-analyses of trials could usefully be 
developed for pain treatments, including a focus on the values and preferences of both patients 
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complexity be reduced as much as possible. A recent survey of clinicians across 8 Western 
countries found that clinicians differentially understand various approaches to presenting 
treatment effects. Methods that employ dichotomized continuous outcomes (e.g., risk reduction) 
were considered by clinicians to be the most accessible, although the percentage of clinicians 
who correctly interpreted these methods was still below 50% [62]. Efforts to extend these 
findings to evaluate the information stakeholders want from RCTs, and how to educate 
stakeholders on the judicious use of both continuous and dichotomized data and the limitations 
of these data, would be valuable. Additionally, experimental research comparing different 
communication strategies and their effects on decision making and clinical outcomes would help 
us to understand the potential risks of these communication strategies.  
 
9. Conclusions 
Interpreting RCTs and their implications for clinical practice can be complicated due to 
the variety of methods that researchers use to report their findings. Becoming familiar with 
typical reporting approaches, as well as their strengths and limitations (see Table 4 for 
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Figure 1 
Interpretation of confidence intervals 
 
Figure 2 






































































Term Explanation and example 
Absolute risk reduction (ARR) The treatment group difference in the 
percentages of participants experiencing an 
event (e.g., the difference in the percentages 
placebo arms). 
Analysis of means Statistically analyzing the between-group 
difference in mean outcome. 
Between-group difference The difference in mean outcome between two 
groups. 
Example: The mean of the change between 
baseline and week 12 on a 0-10 NRS for 
participants in the active treatment group 
minus the same quantity for participants in 
the placebo group. 
Between-group minimal clinically meaningful 
difference 
The between-group difference in an RCT 
(i.e., amount of additional pain reduction in 
the treatment group beyond that observed in 
the comparator group) that is meaningful to 
patients or other stakeholders. There is no 
universally accepted difference between 
treatment and comparator that is considered 
to be clinically important. 
Confidence intervals (CIs) At a given level of confidence (e.g., 95%), the 
range of possible values that are expected to 
contain the true treatment effect. For 
example, if the RCT were replicated a large 
number of times, 95% of the 95% CIs from 
the RCTs would contain the true treatment 
effect 
Cumulative distribution function (CDF) 
each study arm across the range of possible 
responses (see Figure 2). 
Duration of effect The length of the treatment benefit. 
Explanatory trials Trials designed to test whether the treatment 
is efficacious in more highly controlled 
settings (e.g., in a relatively homogeneous 
population).  
Number needed to harm (NNH) Identical to NNT, except NNH evaluates 
percentages of patients with harms. 
Number needed to treat (NNT) The reciprocal of the treatment group 
difference in the percentages of participants 
experiencing an event, calculated as 1/ARR. 
This number can be used, for example, to 
indicate the number of patients who would 
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arm. 
Power Probability of rejecting the null hypothesis of 
no treatment effect when the treatment 
actually has an effect of a specified 
magnitude; calculated as 1  Prob(Type II 
error). 
Pragmatic trials Trials designed to test whether a treatment 
that has been shown to have analgesic 
efficacy is effective in more real-world 
settings (e.g., in a heterogeneous population, 
concomitant medications allowed).  
Primary outcome The prespecified measure on which the effect 
of the treatment is being evaluated. 
Relative risk (RR) The ratio of the participants experiencing an 
event in the treatment arm to that in the 
placebo arm (e.g., the percentage of 
the percentage of 
arm). 
 A comparison between treatment groups of 
individuals who have had a certain 
percentage improvement in pain intensity 
from baseline to end-of-study). 
Treatment risks All adverse events (AEs) associated with a 
treatment as identified by subject symptom 
reports and clinician-observed signs. 
Type I error Probability of rejecting the null hypothesis of 
no treatment effect (e.g., no treatment group 
difference in outcome) when the treatment 
actually has no effect; typically set at 
0.05. 
Type II error Probability of failing to reject the null 
hypothesis of no treatment effect when the 
treatment actually has an effect of a specified 
magnitude; typically set at  0.20.  
Within-group difference The mean change within one treatment group 
between baseline and a defined follow-up 
time period.  
Example: The mean of the change between 
baseline and week 12 on a 0-10 NRS for 
participants in the placebo group. 
Within-patient minimal clinically meaningful 
change 
The within-person change in pain intensity 
that is meaningful to the individual. Typically 
considered to be > 10-20% improvement on 
the 0-10 NRS, with > 30% improvement on 
the 0-10 NRS considered moderate 
improvement, though baseline levels of pain 
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Table 2 
Major factors to consider in determining the clinical importance of group differences (adapted 
from Dworkin et al. [23]) 
____________________________________________________________________________ 
 Statistical significance of the primary efficacy analysis (typically necessary but not sufficient 
to determine that the group difference is clinically meaningful) 
 Availability of alternative therapies and their benefit-risk profiles 
 Treatment effect size for the primary outcome variable compared to that of available 
treatments 
 Safety and tolerability 
 Rapidity of onset of treatment effect 
 Durability of treatment effect 
 Results for secondary efficacy endpoints (e.g., improvements in physical or emotional 
functioning) 
 Limitations of available treatments 
 Different mechanism of action vs. existing treatments 
 Cost, convenience, and patient adherence 
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Table 3 
Innovative clinical trial designs that can be considered in studies of pain treatments 
____________________________________________________________________________ 
Multi-period cross-over trials  Cross-over trials with multiple periods (e.g., 2 active treatment 
periods, 2 placebo or comparator periods) allow for determination of the extent to which the 
effect of a treatment relative to placebo varies among patients [21] 
 
Enrichment clinical trials  Clinical trials in which patients are selected based on a given 
characteristic that is expected to increase the likelihood of detecting a treatment effect [118], for 
example: 
 Enriched Enrollment Randomized Withdrawal (EERW)  Clinical trials in which 
participants are initially administered the treatment of interest and those who 
reach a threshold of improvement and/or tolerability are then randomized to 
either remain on treatment or be withdrawn from treatment [65, 84] 
 
Designs that might reduce placebo group improvement and increase assay sensitivity 
 Sequential Parallel Comparison Design (SPCD)  Clinical trial design in which 
participants are randomized to active treatment or placebo, and then participants 
-randomized to active treatment or 
placebo [37] 
 Two-way Enriched Design (TED)  Clinical trial design in which participants are 
randomized to active treatment or placebo, and then participants who do not 
-randomized to active treatment or placebo and 
-randomized to active treatment or 
placebo [59]  
 
Adaptive designs  Clinical trial designs that prospectively plan for modifications to the design 
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compromising the integrity or validity of the trial [117], for example: 
 Interim sample size re-estimation  Most commonly practiced as estimating 
nuisance parameters (e.g., standard deviation) while the study is ongoing in 
order to determine whether the assumptions underlying the original sample size 
calculation are reasonable and, if not, increasing the sample size as needed [91] 
 Interim efficacy/futility analyses  Comparing treatment arms while the study is 
ongoing to determine whether there is overwhelming evidence supporting either 
the efficacy or futility of the active treatment based on pre-specified stopping 
rules [91] 
 
Master protocol  A protocol containing multiple sub-studies that examine combinations of 
treatments, patient types, or diseases to increase the efficiency of drug development [110, 125]:  
 Basket  Study of 1 treatment in multiple conditions [110, 125] 
 Umbrella  Study of a predetermined set of multiple treatments in 1 condition 
[110, 122] 
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Table 4 
Considerations for reporting and interpreting efficacy outcomes from chronic pain clinical trials 
 
Analysis of means 
 
 Requires specific pre-specified outcome variable at a specific time period 
 Identifying the benefit of a treatment beyond that of the comparator requires 
statistically comparing treatment groups (e.g., active treatment vs. placebo) 
 Tables or figures reporting a week-by-week analysis of means data may 
provide insight into the onset and durability of treatment response 
 If figures are presented for secondary outcomes, they should not detract from 
the presentation of the primary endpoint analyses 
 Sample size and amount of missing data should be reported, and appropriate 
statistical methods should be used to account for missing data along with 
reporting the assumptions underlying those methods 
 
Responder analyses 
  Requires understanding of a clinically meaningful threshold of change 
  Those with a response meeting the pre-established threshold should not be 
active treatment and placebo at the individual level  
  Dichotomizes continuous data into categorical data and, hence, reduces 
information 
  Typically requires larger sample sizes to have sufficient power to detect a 
statistically significant difference between the treatment and comparator arms 
  May be valuable as a secondary analysis to assist in interpreting RCT results 
 
Number needed to treat (NNT), number needed to harm (NNH), relative risk (RR) 
  See considerations for responder analyses above 
  NNTs represent the number needed to be treated to achieve 1 additional 
comparator arm (frequently misinterpreted to represent the number needed to 
 
  RRs may be easier to interpret than NNTs or NNHs  represents the 
 
  Patient characteristics must be considered (i.e., NNTs, NNHs, RRs are specific 
to the sample used to generate them and may not generalize)  
  RRs are frequently interpreted as an exaggerated risk of benefit when 
presented without the absolute risk. 
 
Cumulative distribution functions (CDFs) 
  Continuous plot of percentages of participants in each treatment arm who 
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change 
  Visually reflects the difference between the treatments, and may be valuable 
alongside analysis of means 
  CDFs should be complete, not truncated, and properly account for missing data 
 
Within-patient minimally clinically important difference 
  Reflects a within-patient change (i.e., amount of change required from study 
baseline to end-of-study that is considered to be clinically important), not a 
between-group difference 
  May not equate to well-managed pain 
  Determined empirically with patient input 
 
Time to effect and duration of effect 
  Data on time to effect and duration of effect may contribute to a more complete 
understanding of the overall treatment effect 
   
  Various methods exist to report time to effect and duration of effect 
  Research typically does not examine long-term treatment efficacy, despite 
extended use in the treatment of chronic pain conditions 
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